지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.95 No.2
- 발행연도
- 2018.8
- 수록면
- 111 - 120 (10page)
이용수
초록· 키워드
오류제보하기
Purpose: Response to preoperative transarterial chemoembolization (TACE) has been recommended as a biological selection criterion for liver transplantation (LT). The aim of our study was to identify optimal timing of living donor liver transplantation (LDLT) after TACE based on the TACE response.
Methods: We performed a retrospective study to assess recurrence in 128 hepatocellular carcinoma (HCC) patients who underwent LDLT following sequential TACE from January 2002 to March 2015 at a single institute. Cox proportional hazard models and Kaplan-Meier analysis were utilized to estimate HCC recurrence and find optimal timing for LDLT.
Results: Seventy-three and 61 patients were divided as the responder and nonresponder, respectively. Multivariate analysis showed independent pre-liver transplantation (pre-LT) predictors of recurrence were larger sized tumor (>3 cm, P = 0.024), nonresponse to TACE (P = 0.031), vascular invasion (P = 0.002), and extrahepatic nodal involvement (P = 0.001). In the 3-month time difference between last pre-LT TACE and LDLT subgroup, TACE responders showed significantly higher adjusted hazard ratio (aHR) of recurrence free survival (aHR, 6.284; P = 0.007), cancer specific survival (aHR, 7.033; P = 0.016), and overall survival (aHR, 7.055; P = 0.005). Moreover, for overall patients and responder groups, the significant time difference between last pre-LT TACE and LDLT was 2 months in the minimum P-value approach.
Conclusion: In selected patients who showed good response to pre-LT TACE, a shorter time interval between TACE and LDLT may be associated with higher recurrence free survival, cancer specific survival, and overall survival.
Methods: We performed a retrospective study to assess recurrence in 128 hepatocellular carcinoma (HCC) patients who underwent LDLT following sequential TACE from January 2002 to March 2015 at a single institute. Cox proportional hazard models and Kaplan-Meier analysis were utilized to estimate HCC recurrence and find optimal timing for LDLT.
Results: Seventy-three and 61 patients were divided as the responder and nonresponder, respectively. Multivariate analysis showed independent pre-liver transplantation (pre-LT) predictors of recurrence were larger sized tumor (>3 cm, P = 0.024), nonresponse to TACE (P = 0.031), vascular invasion (P = 0.002), and extrahepatic nodal involvement (P = 0.001). In the 3-month time difference between last pre-LT TACE and LDLT subgroup, TACE responders showed significantly higher adjusted hazard ratio (aHR) of recurrence free survival (aHR, 6.284; P = 0.007), cancer specific survival (aHR, 7.033; P = 0.016), and overall survival (aHR, 7.055; P = 0.005). Moreover, for overall patients and responder groups, the significant time difference between last pre-LT TACE and LDLT was 2 months in the minimum P-value approach.
Conclusion: In selected patients who showed good response to pre-LT TACE, a shorter time interval between TACE and LDLT may be associated with higher recurrence free survival, cancer specific survival, and overall survival.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (19)
참고문헌 신청
[학술지(정기간행물)] - Mazzaferro V / 1996 / Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis / N Engl J Med 334 : 693 ~ 699
[학술지(정기간행물)] - Kim JM / 2010 / Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation? / Transplant Proc 42 : 821 ~ 824
[학술지(정기간행물)] - Kwon CH / 2007 / HCC in living donor liver transplantation: can we expand the Milan criteria? / Dig Dis 25 : 313 ~ 319
[학술지(정기간행물)] - Otto G / 2013 / How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? / J Hepatol 59 : 279 ~ 284
[학술지(정기간행물)] - Yang SH / 2007 / A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma / Surgery 141 : 598 ~ 609
[학술지(정기간행물)] - Kim JM / 2010 / Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation? / Transplant Proc 42 : 821 ~ 824
[학술지(정기간행물)] - Kwon CH / 2007 / HCC in living donor liver transplantation: can we expand the Milan criteria? / Dig Dis 25 : 313 ~ 319
[학술지(정기간행물)] - Otto G / 2013 / How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? / J Hepatol 59 : 279 ~ 284
[학술지(정기간행물)] - Yang SH / 2007 / A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma / Surgery 141 : 598 ~ 609
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
Clinical and Molecular Hepatology
2021 .01
-
The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
Clinical and Molecular Hepatology
2017 .01
-
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
Clinical and Molecular Hepatology
2020 .01
-
Rare Case of Pyogenic Brain Abscess after Transarterial Chemoembolization in a Patient with Hepatocellular Carcinoma: Case Report and Literature Review
Journal of Liver Cancer
2021 .01
-
Outcomes of liver resection and transarterial chemoembolization in patients with multinodular BCLC-A hepatocellular carcinoma
Journal of Liver Cancer
2024 .09
-
Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery
Journal of Liver Cancer
2020 .01
-
Transcatheter Arterial Chemoembolization Combined with Interferon-α is Safe and Effective for Patients with Hepatocellular Carcinoma after Curative Resection
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Effect of neoadjuvant transarterial chemoembolization followed by resection versus upfront liver resection on the survival of single large hepatocellular carcinoma patients: A systematic review and meta-analysis
Annals of Hepato-Biliary-Pancreatic Surgery
2024 .08
-
Efficacy of Transarterial Chemoembolization Combined with Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Ruptured Massive Hepatocellular Carcinoma Cured by Transarterial Chemoembolization
Journal of Liver Cancer
2020 .01
-
Balloon-occluded transarterial chemoembolization for hepatocellular carcinoma: History, background, and the roles
International Journal of Gastrointestinal Intervention
2020 .01
-
Evaluation of the Outcome after Transarterial Chemoembolization; Refinement of Barcelona Clinic Liver Cancer Stage-B from Eastern Point of View
Journal of Liver Cancer
2016 .01
-
Rupture of hepatocellular carcinoma after transcatheter arterial chemoembolization: A case report
International Journal of Gastrointestinal Intervention
2021 .01
-
Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy
Journal of Liver Cancer
2024 .09
-
Transarterial Chemoembolization Monotherapy in Combination with Radiofrequency Ablation or Percutaneous Ethanol Injection for Hepatocellular Carcinoma
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Outcomes of Living Donor Liver Transplantation in Patients with a History of Ruptured Hepatocellular Carcinoma
대한외과학회 학술대회 초록집
2021 .05
-
Transarterial chemoembolization versus resection for the intermediate stage hepatocellular carcinoma
Clinical and Molecular Hepatology
2016 .01
-
Current role of systemic therapy in transarterial chemotherapy-refractory hepatocellular carcinoma patients
International Journal of Gastrointestinal Intervention
2021 .10
-
Trans-arterial Chemo-Embolization in Treating Elderly Patients with Hepatocellular Carcinoma
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Transarterial chemoembolization using drug-eluting bead compared with radiofrequency ablation for treatment of single small hepatocellular carcinoma: a pilot non-randomized trial
Journal of Liver Cancer
2021 .09
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2018-514-003356267